New injection aims to tame dangerous blood vessel inflammation
NCT ID NCT05380453
Summary
This study tested if adding a medication called secukinumab to a standard steroid taper helps people with newly diagnosed giant cell arteritis stay in remission longer. It involved 151 adults whose disease symptoms were under control. The goal was to see if the drug could delay or prevent painful and dangerous flare-ups, allowing patients to safely reduce their steroid dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
-
Novartis Investigative Site
Würzburg, Bavaria, 97080, Germany
-
Novartis Investigative Site
Göttingen, Lower Saxony, 37075, Germany
-
Novartis Investigative Site
Düsseldorf, North Rhine-Westphalia, 40225, Germany
-
Novartis Investigative Site
Dresden, Saxony, 01307, Germany
-
Novartis Investigative Site
Jena, Thuringia, 07740, Germany
-
Novartis Investigative Site
Bad Abbach, 93077, Germany
-
Novartis Investigative Site
Bad Nauheim, 61231, Germany
-
Novartis Investigative Site
Berlin, 12161, Germany
-
Novartis Investigative Site
Berlin, 12435, Germany
-
Novartis Investigative Site
Berlin, 13125, Germany
-
Novartis Investigative Site
Berlin, 13353, Germany
-
Novartis Investigative Site
Cologne, 51149, Germany
-
Novartis Investigative Site
Dresden, 01067, Germany
-
Novartis Investigative Site
Erlangen, 91054, Germany
-
Novartis Investigative Site
Gommern, 39245, Germany
-
Novartis Investigative Site
Hanover, 30625, Germany
-
Novartis Investigative Site
Herne, 44649, Germany
-
Novartis Investigative Site
Ludwigshafen, 67063, Germany
-
Novartis Investigative Site
Mainz, 55131, Germany
-
Novartis Investigative Site
Minden, 32429, Germany
-
Novartis Investigative Site
München, 81667, Germany
-
Novartis Investigative Site
Rendsburg, 24768, Germany
-
Novartis Investigative Site
Sendenhorst, 48324, Germany
-
Novartis Investigative Site
Trier, 54292, Germany
Conditions
Explore the condition pages connected to this study.